You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ruxolitinib

Showing 301 - 325 of 345
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Myelofibrosis Trial in Worldwide (Placebo, Ruxolitinib, Vismodegib)

Completed
  • Myelofibrosis
  • Placebo
  • +2 more
  • Fort Myers, Florida
  • +12 more
May 4, 2018

Novel Factors Leading to Activated Macrophage Expansion in

Active, not recruiting
  • Covid19
  • SARS-CoV-2 Infection
  • Soton hyperinflammation score
  • HScore
  • Southampton, Hampshire, United Kingdom
    University Hospitals Southampton NHS Foundation Trust
May 25, 2021

JAK Inhibitors in Systemic Sclerosis-associated Interstitial

Recruiting
  • Systemic Sclerosis
  • Interstitial Lung Disease
    • Vandœuvre-lès-Nancy, Grand Est, France
      CHU Nancy
    Jan 19, 2022

    National Project on Vaccines, COVID-19 and Frail Patients

    Recruiting
    • COVID-19
    • +4 more
    • COVID-19 vaccines
    • Bologna, Bologhna, Italy
    • +11 more
    Apr 21, 2021

    Hodgkin's Lymphoma Trial in Belgium, France (Ruxolitinib)

    Completed
    • Hodgkin's Lymphoma
    • Ruxolitinib
    • Brussels, Belgium
    • +9 more
    Aug 21, 2018

    Solid Tumors, Pancreatic Cancer Trial in United States (ruxolitinib, gemcitabine, nab-paclitaxel)

    Terminated
    Has Results
    • Solid Tumors
    • Pancreatic Cancer
    • ruxolitinib
    • +3 more
    • Birmingham, Alabama
    • +4 more
    Jan 15, 2018

    Myelofibrosis, Polycythemia Vera, Thrombocytosis Trial in Rochester, Houston (Ruxolitinib)

    Completed
    Has Results
    • Myelofibrosis
    • +2 more
    • Ruxolitinib
    • Rochester, Minnesota
    • +1 more
    Feb 13, 2018

    COVID-19 Pneumonia Trial in Bangladesh (Baricitinib, Dexamethasone, Remdesivir)

    Recruiting
    • COVID-19 Pneumonia
    • Comilla, Bangladesh
    • +6 more
    Aug 25, 2021

    Polycythemia Vera Trial in Worldwide (ruxolitinib tablets, Best Available Therapy (BAT))

    Completed
    Has Results
    • Polycythemia Vera
    • ruxolitinib tablets
    • Best Available Therapy (BAT)
    • Birmingham, Alabama
    • +101 more
    Feb 8, 2019

    Multiple Myeloma Trial in Highland, Boynton Beach, New York (Ruxolitinib 25 mg, Dexamethasone 40 mg)

    Completed
    Has Results
    • Multiple Myeloma
    • Ruxolitinib 25 mg
    • Dexamethasone 40 mg
    • Highland, California
    • +2 more
    Jan 15, 2018

    Ulcerative Colitis, Thromboembolism Trial in Madrid (Tofacitinib, Infliximab Adalimumab y Golimumab)

    Recruiting
    • Ulcerative Colitis
    • Thromboembolism
    • Madrid, Spain
      Hospital Universitario de La Princesa
    Aug 2, 2022

    Prostate Cancer Trial in United States (Ruxolitinib)

    Terminated
    Has Results
    • Prostate Cancer
    • Ruxolitinib
    • Highland, California
    • +14 more
    Jan 15, 2018

    NSCLC (Non-small Cell Lung Carcinoma) Trial in United States (Ruxolitinib, Placebo, Pemetrexed)

    Terminated
    Has Results
    • NSCLC (Non-small Cell Lung Carcinoma)
    • Ruxolitinib
    • +3 more
    • Phoenix, Arizona
    • +29 more
    Jan 15, 2018

    Myeloproliferative Tumor (MPN), Myelofibrosis,MF Trial in Chengdu (flonoltinib 25mg, flonoltinib 50mg, flonoltinib 100mg)

    Recruiting
    • Myeloproliferative Neoplasm (MPN)
    • Myelofibrosis，MF
    • flonoltinib 25mg
    • +5 more
    • Chengdu, Sichuan, China
      West China Hospital Sichuan University
    Mar 9, 2022

    Pancreatic Cancer Trial in United States (Capecitabine, Ruxolitinib, Placebo)

    Completed
    Has Results
    • Pancreatic Cancer
    • Birmingham, Alabama
    • +38 more
    Jan 15, 2018

    Identification of Novel Targetable Kinases in SR-a GvHD

    Completed
    • Graft Versus Host Disease
      • (no location specified)
      Apr 8, 2020

      Myeloproliferative Tumor (MPN), Myelofibrosis,MF Trial (flonoltinib 25mg, flonoltinib 50mg, flonoltinib 100mg)

      Not yet recruiting
      • Myeloproliferative Neoplasm (MPN)
      • Myelofibrosis，MF
      • flonoltinib 25mg
      • +5 more
      • (no location specified)
      Nov 2, 2021

      Anemia, Primary Myelofibrosis, Secondary Myelofibrosis Trial in Scottsdale, New York (ruxolitinib phosphate, danazol,

      Completed
      Has Results
      • Anemia
      • +2 more
      • ruxolitinib phosphate
      • +3 more
      • Scottsdale, Arizona
      • +1 more
      Sep 15, 2017

      CRC (Colorectal Cancer) Trial in Worldwide (Ruxolitinib, Regorafenib, Placebo)

      Terminated
      Has Results
      • CRC (Colorectal Cancer)
      • Ruxolitinib
      • +2 more
      • Chandler, Arizona
      • +85 more
      Jan 15, 2018

      Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis Trial in Worldwide

      Terminated
      Has Results
      • Primary Myelofibrosis
      • +2 more
      • Scottsdale, Arizona
      • +121 more
      Oct 21, 2021

      Pancreatic Cancer Trial in Worldwide (Ruxolitinib, Placebo, Capecitabine)

      Terminated
      Has Results
      • Pancreatic Cancer
      • Ruxolitinib
      • +2 more
      • Huntsville, Alabama
      • +94 more
      Jan 15, 2018

      Polycythemia Vera Trial in Worldwide (Ruxolitinib, Hydroxyurea (HU), HU-)

      Completed
      Has Results
      • Polycythemia Vera
      • Ruxolitinib
      • +3 more
      • Scottsdale, Arizona
      • +69 more
      Oct 12, 2017

      Breast Cancer Trial in Worldwide (Ruxolitinib, Capecitabine, Placebo)

      Terminated
      Has Results
      • Breast Cancer
      • Ruxolitinib
      • +2 more
      • Birmingham, Alabama
      • +106 more
      Jan 15, 2018

      Head and Neck Squamous Cell Carcinoma Trial (ruxolitinib)

      Withdrawn
      • Head and Neck Squamous Cell Carcinoma
      • ruxolitinib
      • (no location specified)
      Jun 6, 2017

      Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Tumors Trial run by the NCI (75 approved agents, COXEN)

      Completed
      Has Results
      • Urothelial Carcinoma
      • +2 more
      • 75 approved agents
      • COXEN
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Oct 14, 2020